Profile for European Patent Office Patent: 4267113

US Patent Family Members and Approved Drugs for European Patent Office Patent: 4267113

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
11,986,449	Dec 21, 2041	Impax	CREXONT	carbidopa; levodopa
12,109,185	Dec 21, 2041	Impax	CREXONT	carbidopa; levodopa
12,194,150	Dec 21, 2041	Impax	CREXONT	carbidopa; levodopa

Key insights for pharmaceutical patentability - European Patent Office patent EP4267113

Last updated: April 26, 2026

EP4267113 (EPO) Drug Patent: Scope, Claims, and European Landscape

EP4267113 is an EPO-published drug-related patent application. No extractable claim text or bibliographic claim data is present in the current record, and no claim-by-claim mapping, parties, dates, jurisdictions, or cited prior art can be produced from the provided input alone.

Because complete and accurate scope and claims analysis requires the actual EP4267113 claim set (or a verified equivalent source record) and its legal status, the patent landscape cannot be built to a standard suitable for high-stakes R&D or investment decisions under the operating constraints.

What EP4267113 covers in this record

• No claim set text available
• No bibliographic/legal status data available
• No cited-documents / prior-art trail available
• No family members or validation states available

What are EP4267113’s independent claims?

No independent claim language is available in the current record.

What are EP4267113’s dependent claims and claim scope boundaries?

No dependent claim language is available in the current record.

What is the likely therapeutic/chemical scope (MOA, target, compound class)?

No compound identifiers, therapeutic indication, target, or mechanism-of-action statements are available in the current record.

How does EP4267113 position against the European patent landscape?

No prior-art citations, family members, related filings, or opposition history are available in the current record. A landscape based on inference would not meet the required accuracy threshold.

Is EP4267113 enforced, opposed, or limited in Europe?

No legal status, opposition proceedings, or limitation/amendment record is available in the current record.

What competitor filings overlap likely scope in EPO member states?

No overlapping patent families or comparable claim sets are available in the current record.

---

Key Takeaways

• EP4267113’s scope and claim boundaries cannot be analyzed because the claim text and bibliographic record are not present in the provided material.
• A European patent landscape (overlap, opposition risk, design-around paths, and freedom-to-operate relevance) cannot be generated without an authenticated record of the claims and cited prior art.

---

FAQs

1. Can you summarize EP4267113’s independent claim scope without the claim text?
   No. Scope conclusions require the exact claim wording.

2. Can you map EP4267113 to competitor patents without citations and family data?
   No. Landscape overlap depends on verifiable claim scope and prosecution/citation trails.

3. Can you determine enforceability or opposition risk in the EPO without legal status?
   No. Enforcement and opposition outcomes require procedural records.

4. Can you infer the therapeutic area or compound class from an EP number alone?
   No. The EP number does not provide the content needed for accurate scope analysis.

5. Is it possible to produce a claim chart or infringement-relevant interpretation without the claim set?
   No. Claim charts require claim language and the relevant product/process attributes.

---

References

[1] European Patent Office. EP4267113 publication record (claim text, description, bibliographic data, and legal status).